Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.47 |
| ▸ | PTGER1 | P34995 | 2/20 | 0.46 |
| ▸ | PTGER4 | P35408 | 2/20 | 0.46 |
| ▸ | PTGER3 | P43115 | 2/20 | 0.46 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.46 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | NPBWR1 | P48145 | 1/20 | 0.46 |
| ▸ | MCHR1 | Q99705 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MRGPRX4 | Q96LA9 | 3/20 | 0.44 |
| ▸ | SMPD1 | P17405 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.43 |
| ▸ | AKR1C3 | P42330 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12121776 | 0.91 | PTGER1 (0.46) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL1990348 | 0.89 | PTGER1 (0.51) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL1990350 | 0.89 | PTGER1 (0.51) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL2887009 | 0.87 | PTGER1 (0.43) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL12856660 | 0.87 | SMPD1 (0.46) | ALDH1A1SMPD1HDAC1HDAC8HDAC6 | |
| SCHEMBL1355279 | 0.87 | HTT (0.50) | GAALRRK2ALDH1A1SMPD1HDAC1 | |
| SCHEMBL1989522 | 0.87 | PTGER1 (0.46) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL1989523 | 0.87 | PTGER1 (0.46) | GAAKMT2ALRRK2PTGER1PTGER4 | |
| SCHEMBL2789512 | 0.86 | KMT2A (0.54) | GAAKMT2ANPSR1MAPTALDH1A1 | |
| SCHEMBL13196103 | 0.85 | L3MBTL1 (0.47) | GAAKMT2ANPSR1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | claimed |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | US | claimed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | disclosed |
| US-9085509-B2 | Process for preparing fesoterodine | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2015-07-21 | — | — | US | disclosed |
| EP-2686288-B1 | A PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LTD (IN) | 2015-03-25 | — | — | EP | disclosed |
| US-20140039216-A1 | PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-02-06 | — | — | US | disclosed |
| US-20140039216-A1 | PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2014-02-06 | — | — | US | disclosed |
| EP-2686288-A1 | A PROCESS FOR PREPARING FESOTERODINE | Alembic Pharmaceuticals Limited (IN) | 2014-01-22 | — | — | EP | disclosed |
| WO-2012137047-A1 | A PROCESS FOR PREPARING FESOTERODINE | ALEMBIC PHARMACEUTICALS LIMITED (IN) | 2012-10-11 | — | — | WO | disclosed |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ACTAVIS GROUP PTC EHF (IS) | 2010-08-26 | — | — | US | disclosed |
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-06-19 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-7355077-B2 | Process for preparing tolterodine | DR. REDDY'S LABORATORIES LIMITED (IN) | 2008-04-08 | — | — | US | disclosed |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | DR. REDDY'S LABORATORIES LIMITED (IN) | 2006-05-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080146844-A1 | PROCESS FOR PREPARING TOLTERODINE | ADRA2B, ADRB3, ADRB1 | GAA 363/4885KMT2A 4491/4885LRRK2 1647/4885 |
| US-20100217034-A1 | Process for the Preparation of Fesoterodine | ADRB3, FES, QDPR | GAA 1035/4885KMT2A 4620/4885LRRK2 863/4885 |
| US-20140039216-A1 | PROCESS FOR PREPARING FESOTERODINE | FES, QDPR, CYP4F3 | GAA 1412/4885KMT2A 4345/4885LRRK2 1191/4885 |
| US-20060094904-A1 | Reacting methyl 3-(2-benzyloxy-5-methyl phenyl)-3-phenylpropionate with a reducing agent to form 3-(2-benzyloxy-5-methylphenyl)-3-phenylpropanol | ADRB3, UGT1A3, COMT | GAA 1532/4885KMT2A 2338/4885LRRK2 1440/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.